PAM50复发风险评分预测丹麦绝经后激素受体阳性早期乳腺癌患者10年远处复发
该研究基于丹麦全国队列,纳入2000至2003年确诊并接受5年内分泌治疗的绝经后激素受体阳性早期乳腺癌患者,使用Prosigna检测2740例肿瘤组织,最终分析2558例HR+/HER2-样本(含1395例淋巴结阳性)。中位随访9.2年,ROR评分可区分高低危患者,低ROR者10年远处复发风险显著低于高ROR者,提示可识别可免除辅助化疗的患者。
要点
- 淋巴结阴性低ROR和高ROR的10年远处复发风险分别为5.0%和17.8%。
核心结论
- Prosigna ROR评分改善了丹麦全国人群的结局预测,可可靠识别可免除辅助化疗的淋巴结阴性及部分1-3枚阳性淋巴结患者。
研究设计与样本
- 基于丹麦乳腺癌协作组数据库的全国性队列研究,纳入2000至2003年确诊并接受5年内分泌治疗的绝经后激素受体阳性早期乳腺癌患者。
- 2740例原发肿瘤块行Prosigna检测,确定HER2状态后分析2558例HR+/HER2-样本,包括1395例淋巴结阳性患者。
- 采用Fine and Gray模型评估ROR对远处复发的预后价值。
主要发现
- 中位复发随访9.2年。
- 淋巴结阴性低ROR和高ROR的10年远处复发风险分别为5.0%(95%CI 2.9%-8.0%)和17.8%(95%CI 14.0%-22.0%)。
临床怎么用
- 在真实世界环境中,Prosigna可用于识别淋巴结阴性和部分1-3枚阳性淋巴结的HR+/HER2-绝经后早期乳腺癌患者,这些患者可能免于辅助化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of postmenopausal women with hormone receptor-positive early breast cancer treated with 5 years of endocrine therapy alone. Patients and Methods Using the population-based Danish Breast Cancer Cooperative Group database, follow-up data were collected on all patients diagnosed from 2000 through 2003 who, by nationwide guidelines, were treated with endocrine therapy for 5 years. Primary tumor blocks from 2,740 patients were tested with Prosigna and, after determination of human epidermal growth factor receptor 2 (HER2) status, data from 2,558 hormone receptor-positive/HER2-negative samples were analyzed, including 1,395 node-positive patients. Fine and Gray models were applied to determine the prognostic value of ROR for DR. Results Median follow-up for recurrence was 9.2 years. Twenty-six percent of the node-positive patients were classified as low ROR (n = 359) with a DR risk of 3.5% (95% confidence interval [CI], 1.9% to 6.1%) versus a DR risk of 22.1% (95% CI, 18.6% to 25.8%) at 10 years for patients classified as high ROR (n = 648). Node-negative patients classified as low and high ROR had a risk of DR of 5.0% (95% CI, 2.9% to 8.0%) and 17.8% (95% CI, 14.0% to 22.0%), respectively. Luminal B tumors (n = 947; DR risk, 18.4% [95% CI: 15.7% to 21.3%]) had a significantly worse outcome than luminal A tumors (n = 1,474,;DR risk, 7.6% [95% CI: 6.1% to 9.2%]; P < .001). Conclusion Prosigna ROR score improved the prediction of outcome in this nationwide Danish population. In a real-world setting, Prosigna can reliably identify node-negative patients and a significant proportion of patients with one to three positive nodes who can be spared treatment with adjuvant chemotherapy.
引用
- Lænkholm AV, Jensen MB, Eriksen JO, et al. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. J Clin Oncol. 2018. PMID: 29369732. doi:10.1200/JCO.2017.74.6586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。